What is Trasylol?
Trasylol, which has the generic name of aprotinin injection, is manufactured by Bayer AG. Trasylol is a drug used to prevent perioperative blood loss and the need for blood transfusion, in patients undergoing a procedure called coronary artery bypass grafting surgery. This type of heart surgery redirects the blood around clogged arteries, in order to increase the blood-flow and oxygen to the heart. Trasylol is known as a broad-spectrum proteinase inhibitor. The drug is designed to work by blocking the enzymes in the body that dissolve blood clots. Trasylol received approval by the FDA in 1993. Worldwide Trasylol sales were approximately $210 million for 2005.
Link Between Trasylol and Kidney Failure
The FDA has issues a public health advisory for Trasylol, after two scientific publications have linked Trasylol to higher risks of harmful side effects, including kidney problems, heart attacks, and strokes. One study published in the New England Journal of Medicine dealt with patients treated with either Trasylol, or two other drugs designed to limit perioperative bleeding called aminocaproic acid, tranexamic acid. Some patients in the study were given no specific drug treatment at all. The study reports that the Trasylol patients had double the risk of harmful side effect that includes kidney damage and an increased risk of heart problems when compared to other drugs. This was an observational study involving patients at 69 medical institutions worldwide. The study looked at 4,374 heart surgery patients who had received one of the clotting drugs and 1,374 patients who received no treatment at all. Trasylol patients accounted for 1,295 of those studied, while 883 patients were treated with aminocaproic acid and 822 with tranexamic acid. The Trasylol patients had twice the risk of kidney failure that required dialysis and a 55 percent increased risk of heart attack or heart failure. In the study the patients who took the other two generic drugs did not suffer an increased risk of harmful side effects. A second recent study published in the on-line edition of Transfusion, also dealt with patients undergoing cardiac surgery that were treated with Trasylol or another drug to decrease perioperative bleeding. The study reported that Trasylol patients had an increased risk of renal dysfunction when compared to patients who received alternative treatment.
 Contact us regarding Trasylol; attorney consultations are free.
Trasylol FDA Advisory
The FDA has advised physicians to carefully monitor their patients for toxicity of the kidneys, heart, and central nervous system. Physicians have also been advised by the FDA to consider limiting use of Trasylol to situations "where the clinical benefit of reduced blood loss is essential to medical management of the patient and outweighs the potential risks." http://www.fda.gov/cder/drug/advisory/aprotinin.htm
Questions and Consultations
If you or a family member has used the prescription drug Trasylol and noticed adverse side effects, such as kidney failure or heart attack, you should contact a physician immediately. If you would like to discuss your rights, are interested in more information on Trasylol litigation, or if you have information about the cases that you would like to share with us, please fill out the short evaluation form below and a member of Seeger Weiss LLP's experienced staff will call you to discuss your potential rights concerning Trasylol. Attorney consultations incur no obligation on your part and all initial consultations are free of charge and do not create an attorney-client relationship. Seeger Weiss LLP has office locations in both New York and New Jersey and its attorneys practice in courts throughout the country.
Link To Lawyer Seek's Trasylol Content:
<a href='http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Trasylol-P109/'>Trasylol: Lawyer Seek</a> |
|
